Kenney Blewett was gasping for air. The 64-year-old from Kyle, Texas, had spent decades fighting chronic obstructive pulmonary disease, a condition that affects sixteen million Americans and had tethered him to his home, his world shrinking with every laboured breath. In June, his doctor prescribed a new inhaled medication that offered genuine hope. The prescription sat unfilled for days, caught in a bureaucratic tangle between insurers. On 7 June, during a severe flare-up, Kenney took his own life. His wife Cindy is left with a haunting question: would he still be here if the medication had arrived in time?
A prescription trapped in the system
Kenney had lost forty-five pounds in recent months. He rarely left the house. His COPD, linked to years of smoking, was advancing with cruel speed. When his physician wrote the prescription for a new inhaler, the couple believed relief was coming. Instead, they received an email from Walgreens citing an “insurance issue.” No further explanation. No timeline.
Cindy called the pharmacy. An employee told her the prescription required “prior authorisation” — a process requiring doctors to secure permission from insurers before treatment can begin. But nobody could tell her which insurer was blocking the path.
Kenney was covered by Medicare, the federal programme for seniors and those with disabilities. He had a Part D plan through Wellcare Value Script, managed by Centene, for prescription drugs. He also held a Medigap policy through Blue Cross and Blue Shield of Texas for out-of-pocket costs. The medication should have fallen under Part B coverage. Yet the government had no record of the prescription ever being billed.
The prior authorisation maze
Prior authorisation has become a flashpoint in American healthcare. Insurers argue it prevents unnecessary spending. Doctors and patients say it delays — and sometimes denies — life-saving care.
In January, a poll by the non-profit KFF found nearly seventy percent of adults consider prior authorisation a major problem. More than ninety percent of physicians surveyed by the American Medical Association in May said the practice delays access to care and harms patient outcomes. Over a quarter reported it had led to an adverse event for a patient.
The Blewetts’ story is not unique. In September 2025, a West Virginia father died of cancer after his insurer reportedly delayed coverage for a potential treatment. KFF Health News documented that case, too.
Promises made, progress questioned
In June 2025 — less than a year before Kenney’s death — health insurers pledged to overhaul prior authorisation. UnitedHealthcare announced it would eliminate thirty percent of requirements starting this week. Chris Klomp, who oversees Medicare for the Trump administration, told the New York Times in May that companies have made progress but much more remains undone.
AHIP, the industry trade group in Washington, declined to comment on individual cases but acknowledged “more needs to be done to fix the fragmented and complex nature of our healthcare system.”
Blue Cross and Blue Shield of Texas told The Independent it does not discuss specific member inquiries, adding only that it is “committed to expanding access to quality, cost effective care at all stages of life.” The Independent has also approached Cindy Blewett, Walgreens, the Centers for Medicare & Medicaid Services, and Centene for comment.
A husband, a father, a life cut short
Kenney had attempted suicide years earlier. He carried the weight of long-term mental health struggles. In a note, he wrote that his health was too poor to continue living. But Cindy wonders whether the acute flare-up on 7 June — the one the new medication might have eased — was the final blow.
“He was hopeful that it would work,” she told KFF Health News. “I wish we had the chance to find out.”
Why it Matters
Kenney Blewett’s death lays bare the human cost of administrative inertia. Prior authorisation is not merely paperwork; for patients like Kenney, it is the difference between breathing and suffocating, between hope and despair. The system failed him at the precise moment he needed it to work. Until insurers, regulators, and providers treat timely access to medication as a moral imperative rather than a negotiable metric, more families will be left asking the same agonising question: what if the delay had never happened?
